Lyka Labs' Q2 FY 2025-26 Quarterly Results

Result Summary

• Lyka Labs Ltd reported a 12.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 8.3%.
• Its expenses for the quarter were up by 30.5% QoQ and 9.5% YoY.
• The net profit decreased 425.3% QoQ and decreased 253.3% YoY.
• The earnings per share (EPS) of Lyka Labs Ltd declined at 0.94 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Lyka Labs Ltd is a pharmaceutical company that is primarily engaged in the production and distribution of a wide array of pharmaceutical products. These products include formulations and active pharmaceutical ingredients (APIs). The company operates in the healthcare sector, a critical industry focused on addressing the medical needs of populations by providing essential medications. As of now, there is no specific information available regarding any recent major developments or strategic shifts within Lyka Labs Ltd. The company continues to focus on its core business of manufacturing and supplying pharmaceuticals to various markets.

Revenue

In the second quarter of fiscal year 2026 (Q2FY26), Lyka Labs Ltd reported a total income of ₹37.75 crores. This represents a quarter-over-quarter (QoQ) increase of 12.2% from the previous quarter (Q1FY26), where total income was ₹33.66 crores. However, on a year-over-year (YoY) basis, there was an 8.3% decline compared to the second quarter of the previous fiscal year (Q2FY25), when the total income was ₹41.18 crores. These figures reflect the company's revenue performance over the respective periods, highlighting fluctuations in income levels.

Profitability

In Q2FY26, Lyka Labs Ltd recorded a profit before tax (PBT) of -₹4.38 crores, marking a significant decline from both Q1FY26 and Q2FY25, where the PBT was ₹1.35 crores and ₹2.67 crores, respectively. The QoQ change for PBT was marked at -424.4%, and the YoY change was -264.0%. The company also reported a profit after tax (PAT) of -₹3.22 crores for Q2FY26, compared to ₹0.99 crores in Q1FY26 and ₹2.10 crores in Q2FY25, indicating a QoQ decline of 425.3% and a YoY decline of 253.3%. Earnings per share (EPS) also saw a decline, moving from ₹0.25 in Q1FY26 and ₹0.58 in Q2FY25 to -₹0.94 in Q2FY26, with QoQ and YoY changes of -476.0% and -262.1%, respectively.

Operating Metrics

The total expenses for Lyka Labs Ltd in Q2FY26 were reported at ₹42.14 crores, which signifies a 30.5% increase from Q1FY26, where the expenses were ₹32.30 crores. Comparing to Q2FY25, where expenses were ₹38.50 crores, there was a YoY increase of 9.5%. The tax component decreased significantly to -₹1.17 crores in Q2FY26 from ₹0.36 crores in Q1FY26 and ₹0.76 crores in Q2FY25, reflecting QoQ and YoY changes of -425.0% and -253.9%, respectively. These figures provide insight into the company's operational cost management and tax obligations over the periods analyzed.